drugset / Trial / NCT07078955
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
Timeline
- Start
- 2025-12
- Primary completion
- 2026-11
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BRM421 | Unknown | 0.03 % | Topical |
| Comparator | BRM421 | Unknown | 0.06 % | Topical |